ReShape Lifesciences Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 8.68 million compared to USD 11.24 million a year ago. Net loss was USD 11.39 million compared to USD 46.21 million a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.162 USD | -4.59% | -2.40% | -34.76% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.76% | 3.98M | |
+8.36% | 219B | |
+6.30% | 183B | |
+10.55% | 133B | |
+24.68% | 108B | |
+0.27% | 63.06B | |
+12.03% | 52.02B | |
+3.96% | 48.2B | |
-0.03% | 40.37B | |
+14.61% | 39.35B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023